| Tecentriq (atezolizumab) / Roche |
| Completed | N/A | 215 | NA | Cisplatin injection, Atezolizumab injection | Shanghai Zhongshan Hospital, Fudan University, Shanghai Jiao Tong University School of Medicine | Urothelial Carcinoma | 08/20 | 11/22 | | |
| Completed | N/A | 279 | RoW | Transarterial chemoembolization, TACE, Systemic treatment | Zhejiang University | Hepatocellular Carcinoma | 03/23 | 10/23 | | |
| Active, not recruiting | N/A | 45 | Europe | 89Zr-MPDL-3280A-PET scans | University Medical Center Groningen | Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression | 11/20 | 06/24 | | |
NCT06323382: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 240 | RoW | Locoregional therapy, TACE/HAIC, Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab | Sun Yat-sen University | Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab | 12/24 | 12/24 | | |
ABCHCaen, NCT06416683: Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma |
|
|
| Completed | N/A | 109 | Europe | | University Hospital, Caen | Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | 06/23 | 01/24 | | |
NCT06199297: Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma |
|
|
| Completed | N/A | 188 | RoW | Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy | Sun Yat-sen University | Hepatocellular Carcinoma | 07/23 | 07/23 | | |
CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1 | Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC) | Cholangiocarcinoma Non-resectable | 12/24 | 06/25 | | |
| Withdrawn | N/A | 20 | Europe | 89Zr-atezolizumab PET scans | University Medical Center Groningen, Amsterdam UMC, location VUmc, Stichting Hemato-Oncologie voor Volwassenen Nederland, Hoffmann-La Roche | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 05/22 | 05/22 | | |
ChiCTR2100052788: a real world study about efficacy and safety of atezolizumab plus chemotherapy in extensive stage small cell lung cancer |
|
|
| Recruiting | N/A | | | Subject to standard treatment regimen of atezolizumab + carboplatin/cisplatin + etoposide ;Standard chemotherapy regimen of carboplatin/cisplatin + etoposide | Beijing Cancer Hospital; Beijing Cancer Hospital, Beijing Hengji Health Management Development Foundation | small cell lung cancer (SCLC) | | | | |
| Completed | N/A | 826 | RoW | TACE+ICIs, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 05/22 | 02/23 | | |
NCT03035890: Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 35 | US | Radiation, Hypofractionated Radiation, Immuno-Therapeutic Agent, Immunotherapy | West Virginia University, West Virginia Clinical and Translational Science Institute | Non Small Cell Lung Cancer Metastatic | 06/22 | 06/22 | | |
NCT04639284: Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC |
|
|
| Recruiting | N/A | 200 | RoW | Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 07/22 | 07/23 | | |
ChiCTR2200061793: Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: a preliminary multicenter single-arm prospective study |
|
|
| Completed | N/A | 30 | | None | The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University; The Third Affiliated Hospital of the Third Affiliated Hospital of the Naval Medical University, Self-raised | hepatocellular carcinoma complicated with portal vein tumor thrombus | | | | |
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study |
|
|
| Terminated | N/A | 3 | RoW | Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab | Peter MacCallum Cancer Centre, Australia | Cancer | 12/22 | 12/22 | | |
NCT04862949: Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC |
|
|
| Completed | N/A | 124 | RoW | Atezolizumab plus bevacizumab | CHA University, Hoffmann-La Roche | Advanced Hepatocellular Carcinoma | 12/22 | 03/23 | | |
NCT04869501: Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer |
|
|
| No Longer Available | N/A | | US | TJ004309, Atezolizumab, Tecentriq | I-Mab Biopharma US Limited | Cancer | | | | |
J-TAIL-2, NCT04501497: Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer |
|
|
| Completed | N/A | 1221 | Japan | | Chugai Pharmaceutical, Japan Lung Cancer Society | Non-small Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer | 02/23 | 02/23 | | |
NCT03559647: The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy |
|
|
| Completed | N/A | 358 | Europe | Atezolizumab | Hoffmann-La Roche | Non-Small Cell Lung Cancer (NSCLC) | 08/23 | 08/23 | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
EXIT, NCT05934214: EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database |
|
|
| Completed | N/A | 141630 | Europe | Immune checkpoint inhibitor | Groupe Hospitalier Pitie-Salpetriere, Institut Curie | Cancer, Immune-related Adverse Event, Immune Checkpoint Inhibitor-Related Myocarditis | 12/23 | 02/24 | | |
| Recruiting | N/A | 221 | Europe | Treatment with immune checkpoint inhibitors., Blood tests. | Hospital Universitario Araba, Hospital de Basurto, Hospital Donostia, Complejo Hospitalario de Navarra, Hospital Galdakao-Usansolo | Cancer, Metastatic Cancer, Solid Organ Cancer | 10/23 | 12/23 | | |
IBFIC, NCT05260606: Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 100 | RoW | F-18 FDG PET/CT | Samsung Medical Center | Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors | 12/25 | 12/25 | | |
PETNEC, NCT04564482: PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer |
|
|
| Recruiting | N/A | 20 | Europe | CRT, SCPRT, CROSS Protocol, PD-L1 PET | Johannes Laengle, MD, PhD, Christian Doppler Laboratory Applied Metabolomics | Rectal Cancer Stage, Oesophageal Cancer | 12/25 | 06/26 | | |
CHANCE023, NCT06024252: Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study |
|
|
| Not yet recruiting | N/A | 200 | NA | TACE, Atezolizumab, Bevacizumab | Zhongda Hospital | HCC | 12/23 | 06/24 | | |
NCT04680598: Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study |
|
|
| Recruiting | N/A | 800 | RoW | ICI, Antiviral Prophylaxis | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital, ZhongShan People 's Hospital | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT04924374: Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy |
|
|
| Recruiting | N/A | 20 | Europe | Microbiota Transplant plus anti PD1 therapy, anti PD1 therapy Pembrolizumab, Nivolizumab, Atezolizumab, anti PD1 therapy, Pembrolizumab, Nivolizumab, Atezolizumab | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Lung Cancer | 12/23 | 07/24 | | |
NCT05173298: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab |
|
|
| Recruiting | N/A | 100 | RoW | atezolizumab plus bevacizumab | CHA University, Boryung Pharmaceutical Co., Ltd | Advanced Hepatocellular Carcinoma | 07/24 | 12/24 | | |
| Recruiting | N/A | 300 | RoW | TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga | Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma Non-resectable | 12/23 | 12/24 | | |
NCT06205732: A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. |
|
|
| Recruiting | N/A | 100 | RoW | Immunotherapy, targeted therapy. | Qianfoshan Hospital | Carcinoma, Hepatocellular | 12/24 | 12/24 | | |
NCT06244446: Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. |
|
|
| Not yet recruiting | N/A | 40 | RoW | No intervention | Institute of Liver and Biliary Sciences, India | Advanced Hepatocellular Carcinoma | 01/25 | 01/25 | | |
ISABELLA, NCT05402059: Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice |
|
|
| Recruiting | N/A | 1570 | RoW | surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines | MelanomaPRO, Russia | Melanoma, Melanoma (Skin), Melanoma, Uveal, Melanoma Stage IV, Melanoma Stage III, Melanoma, Stage II, Melanoma in Situ, Melanoma, Ocular | 04/24 | 04/25 | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
NCT05763277: Ate-Bev Early Response Prediction Model in Advanced HCC |
|
|
| Recruiting | N/A | 170 | RoW | Early response evaluation | Seoul National University Hospital | Hepatocellular Carcinoma, Atezolizumab-bevacizumab, Response Evaluation | 05/24 | 05/25 | | |
NCT04465942: Immunotherapy in Lung Cancer: Treatment After IO Cessation. |
|
|
| Recruiting | N/A | 300 | Europe | (chemo)immunotherapy, cisplatinum, carboplatinum, pemetrexed, paclitaxel, pembrolizumab, nivolumab, atezolizumab | European Lung Cancer Working Party | Carcinoma, Non-Small-Cell Lung, Immunotherapy | 06/24 | 06/25 | | |
| Recruiting | N/A | 1220 | Europe | pembrolizumab plus axitinib, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, nivolumab plus ipilimumab, avelumab plus axitinib, atezolizumab plus bevacizumab | Hospital of Macerata | Metastatic Renal Cell Carcinoma (mRCC) | 06/24 | 12/24 | | |
| Recruiting | N/A | 30 | RoW | Stereotactic Body Radiation Therapy (SBRT) | Chinese University of Hong Kong | HCC | 03/27 | 03/28 | | |
| Recruiting | N/A | 1800 | Europe | Nivolumab, Opdivo, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Durvalumab, Imfinzi, Tremelimumab, CP-675,206, Atezolizumab, Tecentriq, Bevacizumab, Avastin | CCTU- Cancer Theme, Microbiotica Ltd | Melanoma, Renal Cancer, Lung Cancer | 07/24 | 07/25 | | |
I-STOP, NCT05418660: Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC |
|
|
| Recruiting | N/A | 300 | Europe | Immunotherapy, Nivolumab, Pembrolizumab, Atezolizumab | University of Milano Bicocca, Azienda Ospedaliera San Gerardo di Monza | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
NCT05197504: Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy |
|
|
| Recruiting | N/A | 100 | RoW | atezolizumab plus bevacizumab | CHA University | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | N/A | 12 | Europe | Liver Transplantation | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Hepatocellular Carcinoma | 12/24 | 12/24 | | |
JOCARDITE, NCT04294771: JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors |
|
|
| Recruiting | N/A | 500000 | Europe | ICI, Immune checkpoint inhibitors | Groupe Hospitalier Pitie-Salpetriere | Myocarditis, Cardiomyopathies, Heart Diseases, Cardiovascular Diseases, Pericarditis, Vasculitis | 01/25 | 01/25 | | |
DELINOR, NCT05834348: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. |
|
|
| Recruiting | N/A | 20605 | Europe | lorlatinib, crizotinib, brigatinib, ceritinib, alectinib, atezolizumab, bevacizumab, paclitaxel, carboplatin, docetaxel, erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, pembrolizumab, nivolumab, entrectinib | Pfizer | Non-Small Cell Lung Cancer | 02/25 | 02/25 | | |
IMMUNOVASC, NCT05655663: Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer |
|
|
| Recruiting | N/A | 30 | Europe | Vascular investigation | Centre Henri Becquerel | Head and Neck Cancer, Lung Cancer | 02/25 | 12/25 | | |
| Recruiting | N/A | 69 | US | Blood Testing | University of Colorado, Denver, Cancer League of Colorado | Cancer, Metastatic Cancer | 05/25 | 05/27 | | |
NCT05573282: Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 50 | RoW | Regorafenib combine with ICIs | Sun Yat-sen University | Hepatocellular Carcinoma | 06/25 | 01/26 | | |
KOSMOS-II, NCT05525858: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II |
|
|
| Recruiting | N/A | 1000 | RoW | Alectinib, Alecensa, Atezolizumab, Tecentriq, Erlotinib, Tarceva, Trastuzumab + Pertuzumab, Herceptin + Perjeta, Trastuzumab emtansine, Kadcyla, Vemurafenib, Zelboraf, Bevacizumab + Erlotinib, Avastin + Tarceva, Entrectinib, Rozlytrek, Pralsetinib, Gavreto | Seoul National University Bundang Hospital, Korean Cancer Study Group, Roche Pharma AG | Solid Tumor, Advanced Solid Tumor, Metastatic Cancer | 09/25 | 09/25 | | |
| Recruiting | N/A | 120 | Europe | Quantitative assay of GlypicanPC-3 | Assistance Publique - Hôpitaux de Paris | Hepatocellular Carcinoma | 09/25 | 09/27 | | |
IMMUNOCELL, NCT05044676: Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 120 | Europe | patients with hepatocellular carcinoma | Assistance Publique - Hôpitaux de Paris | Hepatocellular Carcinoma | 09/25 | 09/27 | | |
| Recruiting | N/A | 100 | Europe | Tissue Immune Profile | Fondazione per la Medicina Personalizzata, University of Roma La Sapienza | Metastatic Triple-negative Breast Cancer | 09/25 | 09/25 | | |
LATINA, NCT04158258: A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America |
|
|
| Active, not recruiting | N/A | 2907 | RoW | Bevacizumab, Avastin, Trastuzumab, Herceptin, Ado-trastuzumab emtamsine, Kadcyla, Pertuzumab, Perjeta, Atezolizumab, Tecentriq, Capecitabine | Hoffmann-La Roche, Latin American Cooperative Oncology Group | Breast Cancer | 11/25 | 11/25 | | |
NCT05991206: A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC |
|
|
| Recruiting | N/A | 200 | RoW | | Hunan Province Tumor Hospital | NSCLC | 12/25 | 08/26 | | |
NCT04180072: Atezolizumab Plus Bevacizumab With HCC and HBV Infection |
|
|
| Recruiting | N/A | 48 | RoW | Atezolizumab, Tecentriq, Bevacizumab, Avastin | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Carcinoma, Hepatocellular | 12/25 | 12/25 | | |
HOLMBRAVE, NCT05705791: Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 33 | Europe | QuiremSpheres, 166Holmium microspheres, 166Holmium SIRT | Gustave Roussy, Cancer Campus, Grand Paris | Hepatocellular Carcinoma | 02/26 | 08/26 | | |
TALENTop, NCT04649489: A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev |
|
|
| Recruiting | N/A | 456 | RoW | Atezolizumab, Bevacizumab, Surgery | Jia Fan | Venous Thrombosis | 08/27 | 03/28 | | |
NCT05834413: Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | N/A | 367 | RoW | chemotherapy plus TCM 1&ICIs plusTCM2 placebo, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo | Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital | Lung Cancer | 06/26 | 06/26 | | |
IMreal, NCT03782207: A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice |
|
|
| Active, not recruiting | N/A | 3040 | Europe, RoW | Atezolizumab, Tecentriq | Hoffmann-La Roche | Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma | 07/26 | 07/26 | | |
REFINE-IO, NCT06117891: An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | Atezolizumab, Bevacizumab, Durvalumab, Tremelimumab, | Bayer | Unresectable Hepatocellular Carcinoma | 11/26 | 02/27 | | |
| Recruiting | N/A | 64 | Europe | 89Zr-atezolizumab PET/CT | Karolinska University Hospital | Metastatic Triple-Negative Breast Carcinoma | 12/26 | 05/27 | | |
ChiCTR2300069317: Exploratory study of Clostridium butyricum combined with atezolizumab in adjuvant treatment of resectable non-small cell lung caner |
|
|
| Recruiting | N/A | 20 | | Clostridium Butyricum Tablets | Peking University Cancer Hospital & Institute; Peking University Cancer Hospital & Institute, Hangzhou Yidian Information Technology Co., Ltd.; LinkDoc (Beijing) Co., Ltd. | resectable non-small cell lung caner | | | | |
| Recruiting | N/A | 100 | Europe | Atezolizumab | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Small Cell Lung Cancer | 06/27 | 06/27 | | |
